CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that Australia’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Australian Patent Application No. 2017277666, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular […]
Author: Ken Dropiewski
Alucent Biomedical Wins FDA Approval for U.S. Clinical Study
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. today announced that the U.S. Food & Drug Administration granted an Investigational Device Exemption (IDE) for a U.S. clinical study of AlucentNVS, a unique light-activated, drug-coated balloon catheter technology. “AlucentNVS technology is poised to change the standard of care in treating patients undergoing life- and […]
Synaptive Medical Welcomes Provincial Investment to Expand Manufacturing and R&D Activities
TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) — Synaptive Medical has received $900,000 in support from the Ontario government through the Ontario Together Fund. This funding will support Synaptive Medical’s $2.8 million project to expand manufacturing and research and development activities related to the company’s head-only Magnetic Resonance Imaging (MRI) system. […]
LeMaitre Q2 2023 Financial Results
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results Sales $50.1mm, +19% (+16% organic) vs. Q2 2022 Op. income $9.5mm, +63% (+8% adjusted) Op. […]
Penumbra, Inc. Reports Second Quarter 2023 Financial Results
ALAMEDA, Calif., Aug. 1, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2023. Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency1 compared to the second quarter of […]
ConcertAI’s TeraRecon Adds Mirada Medical to its AI Partner Program and Comprehensive Oncology Imaging Solutions
CAMBRIDGE, Mass., Aug. 2, 2023 /PRNewswire/ — ConcertAI’s TeraRecon, the advanced visualization and clinical AI SaaS company, announced today the integration of MiradaXD, the multi-modality nuclear medicine imaging software by Mirada Medical, into its AI partner program. This expands its ability to support cancer care providers with comprehensive oncology imaging solutions. Mirada […]
Silk Road Medical Reports Second Quarter 2023 Financial Results
SUNNYVALE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2023. “Silk Road is the leading force in stroke prevention for patients with severe […]
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – August 01, 2023
CARLSBAD, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2023 that were approved by the Compensation Committee of its Board of Directors under […]
Imperative Care Announces Positive Real-World Data Demonstrating the Clinical Benefits of the Zoom Stroke Solution in Large Vessel and Distal Vessel Occlusions
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced that new data from studies evaluating the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2023 20th Annual Meeting in San […]
Esperion Reports Second Quarter 2023 Financial Results
ANN ARBOR, Mich., Aug. 01, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2023, and provided a business update. “We posted strong results in the second quarter of 2023, reflecting continued prescription growth and an unwavering commitment to execution of […]


